The BIO International Convention is the world's largest gathering for the biotechnology industry, aimed at fostering innovation and collaboration. It targets professionals across the biotech ecosystem seeking to advance science and tackle global challenges.
The BIO International Convention serves as a critical convergence point for the global biotech community, offering invaluable insights into current advancements and future trends. Attendees can expect a robust agenda filled with keynote presentations from thought leaders, interactive panel discussions, and a multitude of networking opportunities. The convention's comprehensive program aims to inspire collaboration and drive innovation, addressing the significant scientific and regulatory challenges facing the industry today.
What you will learn
Emerging trends in biotechnology.
Innovations in drug development.
Strategies for sustainable biosolutions.
Networking with industry leaders.
Best practices in research and development.
Want to exhibit at this event?
MarketScale can act as a third-party concierge, helping you request exhibitor packages, pricing, and booth availability. No cold calls, no commitment.
Key Highlights
• Keynote speeches from industry pioneers.
• Panel discussions on biotech advancements.
• Workshops on drug development strategies.
• Sessions on global biotech collaboration.
Frequently asked questions
Topics & tracks
MarketScale platform
Exhibiting at this event?
Capture customer testimonials onsite, with your iPhone.
MarketScale turns every booth conversation into a produced video clip, written article, and social posts. No crew. No editing. Done before you land home.
Learn how →sciences articles
Biopharma's $300 Billion Problem Is Driving the Biggest M&A Cycle in a Decade
More than $300 billion in branded pharmaceutical revenue faces patent expiration by 2030. Big Pharma cannot replace it through internal R&D alone. The result is the most aggressive acquisition cycle since before the pandemic, and it is reshaping how the entire life sciences supply chain does business.
Quotient Sciences launches Phase I study of what it calls the first AI-formulated drug in the clinic
Quotient Sciences initiates what it calls the first Phase I trial of an AI-designed oral drug formulation, approved by the UK's MHRA.
Quotient Sciences launches Phase I trial of what it calls the first AI-formulated drug to reach the clinic
Quotient Sciences has initiated a Phase I study of an AI-designed oral formulation, cleared by the MHRA—marking a concrete shift from AI experimentation to clin
MarketScale
MarketScale helps B2B teams cover events like this and turn them into content their market reads. Want to talk through what that looks like?